Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328

Hannes Steiner; Ilaria T. Cavarretta; Patrizia L. Moser; Andreas P. Berger; Jasmin Bektic; Hermann Dietrich; Mohamed H. Zaki; Marian Nakada; Alfred Hobisch; Jeffrey A. Nemeth; Zoran Culig

doi:10.1002/pros.20492

Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328

Hannes Steiner, Ilaria T. Cavarretta, Patrizia L. Moser, Andreas P. Berger, Jasmin Bektic, Hermann Dietrich, Mohamed H. Zaki, Marian Nakada, Alfred Hobisch, Jeffrey A. Nemeth, Zoran Culig

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND. Interleukin-6 (IL-6) is a multifunctional regulator of cellular events in prostate cancer. LNCaP-IL-6+ cells selected in the presence of IL-6 were taken for assessment of effects of the chimeric monoclonal anti-IL-6 antibody CNTO 328. METHODS. Cell viability was assessed after treatment with CNTO 328 by the ATP assay. Expression of Bcl-2 and Bax and activation of signaling pathways were evaluated by Western analysis. Nude mice were inoculated with LNCaP-IL-6+ cells and treated with CNTO 328. The tumors were analyzed by immunohistochemistry for expression of Ki-67, tissue transglutaminase, and vascular endothelial growth factor. RESULTS. CNTO 328 caused a statistically significant inhibition of cell viability. The protein levels of Bcl-2 and the phosphorylation of ERK1/2 mitogen-activated protein kinases were decreased by the anti-IL-6 antibody. Treatment with CNTO 328 yielded an increase in the phosphorylation of signal transducers and activators of transcription factor 3. The mean tumor volume in animals inoculated with LNCaP-IL-6+ cells and treated with CNTO 328 was insignificantly lower than that in animals treated with the control antibody. There was a statistically significant decrease in the percentage of Ki-67-positive cells in CNTO 328-treated tumors. CONCLUSION. CNTO 328 has a potential in prostate cancer therapy and could be further tested in various combination experimental treatments.

Original language	English
Pages (from-to)	1744-1752
Number of pages	9
Journal	Prostate
Volume	66
Issue number	16
DOIs	https://doi.org/10.1002/pros.20492
Publication status	Published - Dec 1 2006

Keywords

Interleukin-6
Monoclonal antibody
Prostate tumor
Targeted therapy
Xenografts

ASJC Scopus subject areas

Urology

Access to Document

10.1002/pros.20492

Cite this

Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. / Steiner, Hannes; Cavarretta, Ilaria T.; Moser, Patrizia L.; Berger, Andreas P.; Bektic, Jasmin; Dietrich, Hermann; Zaki, Mohamed H.; Nakada, Marian; Hobisch, Alfred; Nemeth, Jeffrey A.; Culig, Zoran.

In: Prostate, Vol. 66, No. 16, 01.12.2006, p. 1744-1752.

Research output: Contribution to journal › Article › peer-review

Steiner, Hannes ; Cavarretta, Ilaria T. ; Moser, Patrizia L. ; Berger, Andreas P. ; Bektic, Jasmin ; Dietrich, Hermann ; Zaki, Mohamed H. ; Nakada, Marian ; Hobisch, Alfred ; Nemeth, Jeffrey A. ; Culig, Zoran. / Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. In: Prostate. 2006 ; Vol. 66, No. 16. pp. 1744-1752.

@article{235544a9ff524596a4f613d59acce4e6,

title = "Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328",

abstract = "BACKGROUND. Interleukin-6 (IL-6) is a multifunctional regulator of cellular events in prostate cancer. LNCaP-IL-6+ cells selected in the presence of IL-6 were taken for assessment of effects of the chimeric monoclonal anti-IL-6 antibody CNTO 328. METHODS. Cell viability was assessed after treatment with CNTO 328 by the ATP assay. Expression of Bcl-2 and Bax and activation of signaling pathways were evaluated by Western analysis. Nude mice were inoculated with LNCaP-IL-6+ cells and treated with CNTO 328. The tumors were analyzed by immunohistochemistry for expression of Ki-67, tissue transglutaminase, and vascular endothelial growth factor. RESULTS. CNTO 328 caused a statistically significant inhibition of cell viability. The protein levels of Bcl-2 and the phosphorylation of ERK1/2 mitogen-activated protein kinases were decreased by the anti-IL-6 antibody. Treatment with CNTO 328 yielded an increase in the phosphorylation of signal transducers and activators of transcription factor 3. The mean tumor volume in animals inoculated with LNCaP-IL-6+ cells and treated with CNTO 328 was insignificantly lower than that in animals treated with the control antibody. There was a statistically significant decrease in the percentage of Ki-67-positive cells in CNTO 328-treated tumors. CONCLUSION. CNTO 328 has a potential in prostate cancer therapy and could be further tested in various combination experimental treatments.",

keywords = "Interleukin-6, Monoclonal antibody, Prostate tumor, Targeted therapy, Xenografts",

author = "Hannes Steiner and Cavarretta, {Ilaria T.} and Moser, {Patrizia L.} and Berger, {Andreas P.} and Jasmin Bektic and Hermann Dietrich and Zaki, {Mohamed H.} and Marian Nakada and Alfred Hobisch and Nemeth, {Jeffrey A.} and Zoran Culig",

year = "2006",

month = dec,

day = "1",

doi = "10.1002/pros.20492",

language = "English",

volume = "66",

pages = "1744--1752",

journal = "Prostate",

issn = "0270-4137",

publisher = "Wiley-Liss Inc.",

number = "16",

}

TY - JOUR

T1 - Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328

AU - Steiner, Hannes

AU - Cavarretta, Ilaria T.

AU - Moser, Patrizia L.

AU - Berger, Andreas P.

AU - Bektic, Jasmin

AU - Dietrich, Hermann

AU - Zaki, Mohamed H.

AU - Nakada, Marian

AU - Hobisch, Alfred

AU - Nemeth, Jeffrey A.

AU - Culig, Zoran

PY - 2006/12/1

Y1 - 2006/12/1

N2 - BACKGROUND. Interleukin-6 (IL-6) is a multifunctional regulator of cellular events in prostate cancer. LNCaP-IL-6+ cells selected in the presence of IL-6 were taken for assessment of effects of the chimeric monoclonal anti-IL-6 antibody CNTO 328. METHODS. Cell viability was assessed after treatment with CNTO 328 by the ATP assay. Expression of Bcl-2 and Bax and activation of signaling pathways were evaluated by Western analysis. Nude mice were inoculated with LNCaP-IL-6+ cells and treated with CNTO 328. The tumors were analyzed by immunohistochemistry for expression of Ki-67, tissue transglutaminase, and vascular endothelial growth factor. RESULTS. CNTO 328 caused a statistically significant inhibition of cell viability. The protein levels of Bcl-2 and the phosphorylation of ERK1/2 mitogen-activated protein kinases were decreased by the anti-IL-6 antibody. Treatment with CNTO 328 yielded an increase in the phosphorylation of signal transducers and activators of transcription factor 3. The mean tumor volume in animals inoculated with LNCaP-IL-6+ cells and treated with CNTO 328 was insignificantly lower than that in animals treated with the control antibody. There was a statistically significant decrease in the percentage of Ki-67-positive cells in CNTO 328-treated tumors. CONCLUSION. CNTO 328 has a potential in prostate cancer therapy and could be further tested in various combination experimental treatments.

AB - BACKGROUND. Interleukin-6 (IL-6) is a multifunctional regulator of cellular events in prostate cancer. LNCaP-IL-6+ cells selected in the presence of IL-6 were taken for assessment of effects of the chimeric monoclonal anti-IL-6 antibody CNTO 328. METHODS. Cell viability was assessed after treatment with CNTO 328 by the ATP assay. Expression of Bcl-2 and Bax and activation of signaling pathways were evaluated by Western analysis. Nude mice were inoculated with LNCaP-IL-6+ cells and treated with CNTO 328. The tumors were analyzed by immunohistochemistry for expression of Ki-67, tissue transglutaminase, and vascular endothelial growth factor. RESULTS. CNTO 328 caused a statistically significant inhibition of cell viability. The protein levels of Bcl-2 and the phosphorylation of ERK1/2 mitogen-activated protein kinases were decreased by the anti-IL-6 antibody. Treatment with CNTO 328 yielded an increase in the phosphorylation of signal transducers and activators of transcription factor 3. The mean tumor volume in animals inoculated with LNCaP-IL-6+ cells and treated with CNTO 328 was insignificantly lower than that in animals treated with the control antibody. There was a statistically significant decrease in the percentage of Ki-67-positive cells in CNTO 328-treated tumors. CONCLUSION. CNTO 328 has a potential in prostate cancer therapy and could be further tested in various combination experimental treatments.

KW - Interleukin-6

KW - Monoclonal antibody

KW - Prostate tumor

KW - Targeted therapy

KW - Xenografts

UR - http://www.scopus.com/inward/record.url?scp=33845405558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845405558&partnerID=8YFLogxK

U2 - 10.1002/pros.20492

DO - 10.1002/pros.20492

M3 - Article

C2 - 16998813

AN - SCOPUS:33845405558

VL - 66

SP - 1744

EP - 1752

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 16

ER -

Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this